HealthTech

Syntis Bio

Syntis Bio raises $33M Series A

$33M

Total Raised

Series A

Latest Round

2022

Founded

50+

Employees

Cambridge, MA

Updated June 14, 2025

1 min read

Quick Facts

Latest Round Size

$33M

Latest Round Date

June 2025

Syntis Bio: Series A Funding Round

Syntis Bio has successfully raised $33M in Series A funding.

Company Overview

Developing oral therapies for obesity diabetes and rare diseases

Funding Details

The Series A round was led by Cerberus Ventures.

Investment

Syntis Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

Cerberus Ventures: Verified investor in Series A

Key Investors

Cerberus Ventures

Lead Investor

Verified investor in Series A

Topics

verified(1243)real-funding(1243)healthtech(156)series-a(152)cambridge(27)syntis-bio(1)

About the Author

Editorial Team

Curated funding news from verified sources

Related Company Reports

HealthTech

AccelerateStack Platform

AccelerateStack Platform raises $75M Series C at $226M valuation

AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.

DermaSensor raises $16M Series B at $85M valuation

DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...

Devoted Health Partners

Devoted Health Partners Headquarters - Office Location & Address

Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.